Roche's Hemlibra, Gilead's Biktarvy top pharma's blockbuster 2018 launches: report

Despite concerns that payers are clamping down on new drug launches, a dozen new meds are slated to reel in blockbuster sales in the coming years, according to a new report. In fact, Clarivate Analytics expects pharma to launch more blockbusters in 2018 than in any year in recent history. The analysts this week published a report of 12 "Drugs to Watch" for 2018, featuring meds from Roche, Gilead Sciences, Novo Nordisk, Johnson & Johnson, GlaxoSmithKline and more. In all, the authors expect more blockbuster meds to enter the market in 2018 than in any other year since they've started the report series back in 2013.